Multiple myeloma: open trials in Austria

16 open trials have a site in Austria. Registry data; only the trial team decides who can take part.

NCT06189833
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
Trial Treatment · Phase 2 · European Myeloma Network B.V.
Ordensklinikum Linz GmbH, Linz · Medical University of Vienna, Vienna · Stadt Wien Wiener Gesundheitsverbund, Vienna
Registry updated 2026-11-04
NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Medizinische Universitaet Innsbruck, Innsbruck · Johannes Kepler University Linz, Linz · Noe LGA Gesundheit Region Mitte GmbH, St. Poelten · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna · Klinikum Wels-Grieskirchen GmbH, Wels
Registry updated 2026-11-04
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Ordensklinikum Linz GmbH, Linz · SCRI CCCIT Ges.m.b.H., Salzburg · Medical University of Vienna, Vienna · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Krems · Leoben · Sankt Pölten · Vienna · Vienna
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Ordensklinikum Linz GmbH, Linz · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Universitatsklinik für Innere Medizin Graz, Graz · Medizinische Universitaet Innsbruck, Innsbruck · Ordensklinikum Linz GmbH, Linz · Landeskrankenhaus Feldkirch, Rankweil · Universitätsklinik für Innere Medizin III Salzburg, Salzburg · Universitätsklinikum St. Pölten, Sankt Pölten · Medical University of Vienna, Vienna · Stadt Wien Wiener Gesundheitsverbund, Vienna · Krankenhaus Der Barmherzigen Schwestern Wien Betriebsgesellschaft mbH, Vienna · Klinikum Wels-Grieskirchen GmbH, Wels
Registry updated 2026-10-27
NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Trial Treatment · Phase 3 · Takeda
Ordensklinikum Linz GmbH, Linz · Noe LGA Gesundheit Region Mitte GmbH, St. Poelten · Krankenhaus Der Barmherzigen Schwestern Wien Betriebsgesellschaft mbH, Vienna
Registry updated 2026-10-13
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Vorarlberger Krankenhaus-Betriebsgesellschaft mbH, Feldkirch · Medizinische Universitaet Innsbruck, Innsbruck · Universitaetsklinikum Krems, Krems An Der Donau · Steiermaerkische Krankenanstalten Ges.m.b.H., Leoben · Kepler Universitaetsklinikum GmbH, Linz · Ordensklinikum Linz GmbH, Linz · Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH, Salzburg · Stadt Wien Wiener Gesundheitsverbund, Vienna
Registry updated 2026-10-07
NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Trial Treatment · Phase 3 · Pfizer
Medizinische Universitaet Innsbruck, Innsbruck · Universitaetsklinikum Krems, Krems An Der Donau · University Hospital Salzburg, Salzburg · Stadt Wien Wiener Gesundheitsverbund, Vienna · Medical University of Vienna, Vienna
Registry updated 2026-08-24
NCT06679101
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Trial Treatment · Phase 3 · GlaxoSmithKline
Ordensklinikum Linz GmbH, Linz · SCRI CCCIT Ges.m.b.H., Salzburg · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna · Noe LGA Gesundheit Thermenregion GmbH, Wiener Neustadt
Registry updated 2026-04-22
NCT06932562
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Ordensklinikum Linz GmbH, Linz · Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH, Salzburg · Stadt Wien Wiener Gesundheitsverbund, Vienna
Registry updated 2026-03-25
NCT06237803
European Myeloma Network (EMN) Sample Project
Research · European Myeloma Network B.V.
KUK Linz, Linz · Medical University Vienna, Vienna
Registry updated 2025-12-03
2023-507402-13-00
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
Trial Treatment · Phase 3 · Universitaetsklinikum Heidelberg AöR
Universitaetsklinikum Krems, Krems An Der Donau · Ordensklinikum Linz GmbH, Linz · SCRI CCCIT Ges.m.b.H., Salzburg · Noe LGA Gesundheit Region Mitte GmbH, St. Poelten · Stadt Wien Wiener Gesundheitsverbund, Vienna · Klinikum Wels-Grieskirchen GmbH, Wels
Registry updated 2025-07-09
NCT06821880
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
Research · Medical University Innsbruck
Medizinische Universität Graz, Graz · Medizinische Universität Innsbruck, Innsbruck · BKH Kufstein, Kufstein
Registry updated 2025-02-12
NCT06597916
RSV Vaccination in Immunocompromised Patients.
Trial Treatment · Phase 2 · Medical University of Vienna
Institute of Specific Prophylaxis and Tropical Medicine, CePII, Medical university of Vienna, Vienna
Registry updated 2024-11-27
2024-514702-31-00
Daratumumab in Combination with Carfilzomib, Pomalidomide and Dexamethasone in patients with myeloma induced acute renal failure
Trial Treatment · Phase 2 · Medizinische Universitaet Innsbruck
Medizinische Universitaet Innsbruck, Innsbruck
Registry updated 2024-10-29

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error